| Today’s Big NewsNov 26, 2024 |
|
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
| By James Waldron Amgen claims to have made weight loss history by producing the first proof of a reduction in body weight for a monthly obesity treatment in a phase 2 study—but it wasn’t enough to enthuse investors. |
|
|
|
By Nick Paul Taylor Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, which Roche has said can democratize CAR-Ts, as a new core capability at the drugmaker. |
By Nick Paul Taylor Roche’s SKYSCRAPER-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint inhibitor had no effect on overall survival in non-small cell lung cancer. |
Sponsored by Questex Discover the trailblazers shaping the future of healthcare, biotech, and pharma at the Fierce 50 Awards Gala. |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now.
|
|
By James Waldron Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to its T cell receptor-guided therapies. |
By Gabrielle Masson Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. |
By Gabrielle Masson Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three preclinical—in addition to a discovery partnership with six targets. |
By Kevin Dunleavy Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. The company has handed pink slips to 195 more employees, according to a New Jersey Worker Adjustment and Retraining Notification update. |
By Darren Incorvaia In order to more quickly recruit volunteers into clinical trials, a team of researchers at the NIH has turned to artificial intelligence. The scientists built a large language model, TrialGPT, that can scan medical summaries of patients and match them to clinical trials they are eligible for. |
By Fraiser Kansteiner German CDMO Adragos Pharma has been on a growth tear this year. Now, the manufacturing arriviste—which was founded in 2020—is expanding its production network again with the acquisition of Switzerland's Baccinex, which specializes in fill and finish services. |
By Noah Tong With time running out before leaving office, the Biden administration is proposing a rule to have Medicare and Medicaid cover anti-obesity medications and bolster guardrails for AI. It also addresses prior authorization, behavioral health, brokers, provider directories and vertical integration. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
